Bio Green Med Solution Inc Receivables Turnover Ratio (BGMS), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Bio Green Med Solution Inc   (NASDAQ: BGMS)
 

Bio Green Med Solution Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Bio Green Med Solution Inc 's ability to collect accounts receivable sequentially worsen to 1.75, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Bio Green Med Solution Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 209 days, from 190 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 505 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Bio Green Med Solution Inc Selling?


What is Receivable Turnover Ratio?





BGMS Receivables Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change - - - 710 % -
Receivable Turnover Ratio (TTM) 1.75 1.92 1.51 0.45 -
BGMS's Total Ranking # # # # #
Accounts Receivable average collection period days 208 190 242 817 -
Seq. Receivable Change -9.6 % -5.49 % 73.38 % - -
Seq. Revenue Change -56.81 % 16.82 % 722.22 % - -


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 506
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
1.75 1.75 1.75
(Jun 30 2026)  






Financial Statements
Bio Green Med Solution Inc 's Accounts Receivable $ 1 Millions Visit BGMS's Balance sheet
Bio Green Med Solution Inc 's Sales TTM $ 2 Millions Visit BGMS's Income Statement
Sources of BGMS's Revenues Visit BGMS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
BGMS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
BGMS's Growth Rates BGMS's Roa BGMS's Inventory Turnover Ratio BGMS's Dividend Comparisons
BGMS's Profitability Ratios BGMS's Roi BGMS's Asset Turnover Ratio BGMS's Dividend Growth
BGMS's Valuation Ratios BGMS's Roe BGMS's Financial Strength Ratios BGMS's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Personalis Inc   4.75 $ 69.669  Millions$ 14.676  Millions
Privia Health Group Inc   4.75 $ 2,358.069  Millions$ 496.945  Millions
Globus Medical Inc   4.70 $ 3,144.934  Millions$ 669.166  Millions
Staar Surgical Co  4.69 $ 339.590  Millions$ 72.454  Millions
Bausch and Lomb Corp  4.65 $ 5,324.000  Millions$ 1,144.000  Millions
Kewaunee Scientific Corporation  4.63 $ 275.985  Millions$ 59.584  Millions
Orasure Technologies Inc  4.62 $ 111.978  Millions$ 24.227  Millions
Bristol myers Squibb Company  4.60 $ 49,186.000  Millions$ 10,689.250  Millions
Omniab Inc   4.60 $ 38.457  Millions$ 8.363  Millions
Yunhong Green Cti Ltd   4.58 $ 20.662  Millions$ 4.513  Millions
Orthopediatrics Corp  4.56 $ 251.278  Millions$ 55.123  Millions
Cryo cell International Inc   4.54 $ 31.128  Millions$ 6.851  Millions
Aligos Therapeutics Inc   4.54 $ 31.518  Millions$ 6.945  Millions
Bioventus Inc   4.49 $ 581.106  Millions$ 129.410  Millions
Fulgent Genetics Inc   4.45 $ 322.973  Millions$ 72.541  Millions
Gyre Therapeutics Inc   4.43 $ 119.383  Millions$ 26.928  Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________  4.42 $ 25.185  Millions$ 5.695  Millions
Supernus Pharmaceuticals inc   4.41 $ 830.438  Millions$ 188.224  Millions
Eli Lilly And Company  4.40 $ 79,665.800  Millions$ 18,094.850  Millions
Neurocrine Biosciences Inc   4.40 $ 3,373.900  Millions$ 767.475  Millions
Lantheus Holdings Inc   4.39 $ 1,555.343  Millions$ 354.642  Millions
Waters Corporation  4.38 $ 4,644.249  Millions$ 1,059.341  Millions
Organon and Co   4.31 $ 6,139.000  Millions$ 1,422.750  Millions
Vsee Health Inc   4.30 $ 10.759  Millions$ 2.500  Millions
Alkermes Plc   4.30 $ 1,667.652  Millions$ 388.132  Millions
Glaukos Corp  4.29 $ 500.031  Millions$ 116.471  Millions
Dexcom Inc   4.25 $ 4,968.800  Millions$ 1,168.000  Millions
Vericel Corporation  4.18 $ 306.303  Millions$ 73.289  Millions
Retractable Technologies Inc  4.14 $ 33.488  Millions$ 8.087  Millions
Apyx Medical Corp  4.14 $ 58.105  Millions$ 14.035  Millions

Date modified: 2026-08-15T21:11:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.